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Sensorineural hearing loss (SNHL) is considered an intractable disease, given that hair
and supporting cells (HCs and SCs) of the postnatal mammalian cochlea are unable to
regenerate. However, with progress in regenerative medicine in the 21st century, several
innovative approaches for achieving regeneration of inner ear HCs and SCs have become
available. These methods include stem cell transplantation, overexpression of speciﬁc
genes, and treatment with growth factors. Insulin-like growth factor-1 (IGF-1) is one of
the growth factors that are involved in the development of the inner ear. Treatment with
IGF-1 maintains HC numbers in the postnatal mammalian cochlea after various types of
HC injuries, with activation of two major pathways downstream of IGF-1 signaling. In the
aminoglycoside-treated neonatal mouse cochlear explant culture, promotion of the cell-
cycle in SCs as well as inhibition of HC apoptosis was observed in the IGF-1-treated group.
Activation of downstream molecules was observed in SCs and, in turn, SCs contribute to
the maintenance of HC numbers. Using comprehensive analysis of the gene expression,
the candidate effector molecules of the IGF-1 signaling pathway in the protection of HCs
were identiﬁed as Netrin1 and Gap43. Based on these studies, a clinical trial has sought
to investigate the effects of IGF-1 on SNHL. Sudden SNHL (SSHL) that was refractory
to systemic steroids was treated with IGF-1 in a gelatin hydrogel and the outcome was
compared with a historical control of hyperbaric oxygen therapy.The proportion of patients
showing hearing improvement was signiﬁcantly higher in the IGF-1-treatment group at
24 weeks after treatment than in the control group. A randomized clinical trial is ongoing
to compare the effect of IGF-1 treatment with that of intra-tympanic steroids for SSHL that
is refractory to systemic steroids.
Keywords: apoptosis, cell cycle, clinical trial, MEK/ERK pathway, Netrin1, PI3K/Akt pathway, sensorineural hearing
loss
INTRODUCTION
Sensorineural hearing loss (SNHL) is a common disability. It
includes age-related hearing loss, noise-induced hearing loss,
genetic hearing loss, sudden sensorineural hearing loss (SSHL),
and hearing loss caused by ototoxic drugs (for example, amino-
glycosides). In the United States, about 63% of people older than
70 years have hearing loss (Lin et al., 2011). Profound, early onset
deafness is found in 4–11 per 10,000 children and in 50% of such
cases, the causes are genetic (Marazita et al., 1993). SSHL occurs in
5–20 cases per 100,000 persons annually (Byl, 1984). Despite the
high prevalence, no effective treatment has been established for
SNHL, except for cochlear implants in profound SNHL or steroid
treatment in the cases of acute hearing loss, such as SSHL. Most
SNHL cases are caused by the loss or functional impairment of
hair cells (HCs) in the cochlea, but mammalian HCs have not
been considered to be capable of proliferation during postnatal
stage (Ruben, 1967). Consequently, HCs never regenerate in the
cochlea, a hearing organ in the inner ear, although HCs in the
vestibular organs (utricle and saccule) in the inner ear have min-
imal capacity for regeneration (Forge et al., 1993; Warchol et al.,
1993). This fact has prevented development of effective methods
for treating SNHL. In contrast to mammals, avian inner ear HCs
have been shown to be able to regenerate even after birth (Corwin
and Cotanche, 1988; Jorgensen and Mathiesen, 1988; Ryals and
Rubel, 1988). Regeneration of avian HCs is based on both pro-
liferation (Corwin and Cotanche, 1988; Ryals and Rubel, 1988)
and transdifferentiation (Adler and Raphael, 1996; Baird et al.,
1996) of supporting cells (SCs) that surround HCs. Thus, SCs are
considered to be a source of HC regeneration.
As regenerative medicine emerged in the 21st century, many
researchers have attempted to regenerate mammalian HCs using
various strategies: stemcell transplantation, overexpression of spe-
ciﬁc genes, and treatment with growth factors. Tissue-engineering
technology, which is one of the most powerful tools of regen-
erative medicine, is based on three important factors, namely,
isolated cells, tissue-inducing substances, and scaffold or matrices
into which cells are placed (Langer andVacanti, 1993), all of which
are also necessary for regenerative medicine.
Tissue-inducing substances also include growth factors, which
are humoral factors that bind to their speciﬁc receptors on the cell
membrane to activate intracellular signaling in order to exert their
effects. Since growth factors were ﬁrst extracted from exocrine
or endocrine organs in the 1960’s and 1970’s (Cohen, 1962;
Armelin, 1973), they have been demonstrated to regulate survival,
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proliferation, anddifferentiationof various types of cells in various
organs. These functions prompted the application of some growth
factors to regenerative medicine. For instance, basic ﬁbroblast
growth factor enhances proliferation of epidermal cells, inspir-
ing its use in the treatment of pressure ulcers and other types of
skin ulcer. From the study of hematopoietic stem cells and various
precursor cells of the hematopoietic system, various growth factors
have been identiﬁed as regulating the induction and proliferation
of speciﬁc lineages of hematopoietic cells. Among these growth
factors, erythropoietin and granulocyte-colony stimulating factor
are clinically used to treat anemia and neutropenia, respectively.
These are good examples of the application of growth factors in
regenerative medicine.
In this article, after ﬁrst brieﬂy reviewing the role of growth fac-
tors, particularly insulin-like growth factor-1 (IGF-1), in the inner
ear, we summarize the application of IGF-1 to the treatment of
inner ear disorders in animal models, the mechanisms underlying
the effects of IGF-1 on the inner ear, and a clinical trial of IGF-1
in human SSHL cases.
GROWTH FACTORS AND THE INNER EAR
It has been investigated whether growth factors could induce
proliferation of HCs, which have been reported to lose their
proliferative ability from the embryonic stage (Ruben, 1967).
Growth factors were expected to induce HC proliferation dur-
ing the postnatal stage because they have a marked capacity for
inducing proliferation in treated cells. When neonatal rat utricle
cells were dissociated and cultured, the effect of various types of
growth factors on the proliferation of utricular cells was investi-
gated quantitatively (Zheng et al., 1997). Among several growth
factors tested, epidermal growth factor, transforming growth
factor α, basic ﬁbroblast growth factor, and IGF-1 were able to
induce proliferation. In particular, combination of basic ﬁbrob-
last growth factor and IGF-1 or transforming growth factors α
had additive effects. Similar mitogenic effects were conﬁrmed
for epidermal growth factor and transforming growth factor α in
vestibular organ culture (Lambert, 1994; Yamashita and Oesterle,
1995). Moreover, epidermal growth factor caused supernumer-
ary HC formation even in neonatal mouse cochlear organ culture
(Lefebvre et al., 2000).
INSULIN-LIKE GROWTH FACTOR-1 AND ITS DOWNSTREAM
SIGNALING
Insulin-like growth factor-1 was originally found in human serum
as a factor that stimulates the incorporation of sulfate into car-
tilage (Salmon and Daughaday, 1957). Later, it was shown that
its insulin-like activity was not suppressed by anti-insulin anti-
bodies (Froesch et al., 1963) although its structure was similar
to that of proinsulin (Rinderknecht and Humbel, 1976a). The
insulin-like activity of IGF-1 was 60 times lower than that of
insulin but, in contrast, the [3H]-thymidine incorporation activ-
ity (proliferation-induction activity) of IGF-1 was 50 times higher
than that of insulin (Rinderknecht and Humbel, 1976b). IGF-
1 is a small peptide, comprising 70 amino acids (Rinderknecht
and Humbel, 1978), which acts as an anabolic and mitogenic
effector of growth hormone (Laron, 1999). IGF-1 in the serum
is synthesized mainly in the liver and most of the circulating
IGF-1 forms a complex with its binding proteins, IGFBP1–
6 (Jones and Clemmons, 1995) that modify the activity of
IGF-1.
Insulin-like growth factor-1 exerts its action through its recep-
tor, IGF1 receptor (IGF1R). IGF1R belongs to a family of tyrosine
kinase receptors. Once IGF-1 binds to IGF1R, it induces autophos-
phorylation on the intracellular tyrosine residues (Kato et al., 1994;
Figure 1). Activated IGF1R interacts with and phosphorylates
other intracellular adaptor molecules, viz., the insulin receptor
substrate (IRS) 1–4 and Src homology collagen (Shc) protein
(Myers et al., 1993; Blakesley et al., 1996; White, 1997). Phos-
phorylated IRSs activate phosphatidylinositol-3 kinase (PI3K)
and lead to the formation of membrane-associated phospho-
rylated inositols. These molecules activate phosphoinositide-
dependent kinase, which phosphorylates several other protein
kinases, such as Akt (PI3K/Akt pathway; Figure 1) and pro-
tein kinase C (Vanhaesebroeck and Alessi, 2000). PI3K acti-
vation is involved in the inhibition of apoptosis, regulation
of gene transcription, and mitogenesis (Shepherd et al., 1998).
IGF1R activates another pathway through the recruitment to
both IRS-1 and Shc of Sos via the SH2 domain of Grb2
(Yamauchi and Pessin, 1994). This recruitment leads to the
activation of the small G-protein, Ras, which in turn causes
the activation of Raf. Raf phosphorylates MAPK/ERK kinase
(MEK) and MEK activates the extracellular-signal-regulated
kinase (ERK) in the MEK/ERK pathway (Figure 1; Laviola
et al., 2007). This pathway is mainly involved in mitogenic
(Pagès et al., 1993), transcriptional (Laviola et al., 2007), or
anti-apoptotic responses (Holmström et al., 1999; Finlay et al.,
2000).
FIGURE 1 | Graphical summary of the signaling pathways of IGF-1 and
its downstream effectors, and its effect on the protection of hair cells
(HCS).The mechanisms of HC number maintenance by IGF-1 were
elucidated using several speciﬁc inhibitors (LY294002, Akt inhibitor VIII,
U0126, and PD98059) of the downstream molecules in IGF-1 signaling
pathways. IGF-1 protects HCS against aminoglycosides through activation
of both the MEK/ERK and PI3K/AKT pathways. Akt is involved in the
survival of only inner HCS. MEK/ERK causes cell cycle promotion in
Hensen’s and Claudius’ cells.
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As an effector of growth hormone, IGF-1 is involved in the
anabolic growth of various organs. In addition to this original
role, IGF-1 also regulates, for example in the central nervous sys-
tem, neuronal survival, neurogenesis, angiogenesis, excitatory, and
inhibitory neurotransmission, regulation of food intake, and cog-
nition (Werner and Leroith, 2014). Since recombinant IGF-1 has
been synthesized, it has beenused clinically in replacement therapy
in patients with primary growth hormone-resistance (Laron syn-
drome) where IGF-1 is not synthesized (Laron, 1999). However,
recombinant IGF-1 has been evaluated clinically for the treatment
of other diseases. It has been reported to reduce the requirement
for insulin in type I diabetes mellitus, to reduce the serum lev-
els of lipoproteins, to increase the glomerular ﬁltration and the
tubular reabsorption of phosphate, and to slow the progression
of amyotrophic lateral sclerosis (Laron, 1999). However, because
the mitogenic effects of IGF-1 are involved in the growth regula-
tion of breast (Wolf et al., 1997) and prostate cancer (Chan et al.,
1998; Wang and Wong, 1998) and because patients with IGF-
1 hypersecretion (acromegaly) have a higher incidence of large
bowel polyposis, the use of recombinant IGF-1 should be avoided
in such patients or in those with a family history of these tumors.
IGF-1 AND THE INNER EAR
Since Leon et al. (1995) reported that IGF-1 promotes the growth
of chicken otocysts by inducing cell proliferation during the early
developmental stage of the inner ear, many studies have shown
that IGF-1 and its signaling system plays important roles in the
development or maintenance of the inner ear, and, as a result,
in hearing. In human beings, SNHL occurs in patients with
mutations in Igf1 gene (Woods et al., 1996; Bonapace et al., 2003;
Walenkamp et al., 2005), primary IGF-1 deﬁciency (Attias et al.,
2012), or low serum IGF-1 levels due to other genetic defects (Bar-
renas et al., 2000; Johnson et al., 2007), indicating the importance
of IGF-1 in hearing. Replacement therapy using recombinant
IGF-1 rescues patients from the hearing loss in Laron syndrome
(Attias et al., 2012). The SNHL in Laron syndrome patients is
attributed to cochlear dysfunction, based on otoacoustic emis-
sion test results (Attias et al., 2012). However, in a mouse model of
IGF-1 deﬁciency, that is in IGF-1 knockout mice (Camarero et al.,
2001, 2002; Cediel et al., 2006; Riquelme et al., 2010), the causes
of SNHL were reported as the loss of spiral ganglion neurons,
abnormal myelination of the cochlear nerve, and degeneration
of the stria vascularis, based on the results of morphological
(Camarero et al., 2001, 2002) and auditory brain stem response
studies (Cediel et al., 2006; Riquelme et al., 2010). The stria degen-
eration becomes apparent from the age of 3 months in IGF-1
knockout mice although the loss of spiral ganglion cells com-
mences from the age of 3 weeks (Camarero et al., 2002; Riquelme
et al., 2010). Knocking out of Irs2, a gene encoding an intra-
cellular adaptor molecule of IGF1R, also showed similar inner
ear phenotypes to IGF-1 knockout mice (Murillo-Cuesta et al.,
2012). In contrast to IGF-1 knockout mice, deletion of Igfr1
caused inner ear anomalies (short cochlear duct, truncated lat-
eral semicircular canal, and hypomorphic posterior semicircular
canal), the delay of maturation of HCs and SCs in the cochlea,
and reduced proliferation of prosensory cells in the develop-
ment of the inner ear (Okano et al., 2011). Unfortunately, hearing
phenotypes and mature inner ear morphology could not be stud-
ied because of the embryonic lethality caused by Igf1r knockout.
Comparable phenotypes were reproduced with the treatment of
IGF1R inhibitors on the embryonic cochlear explant culture.
These IGF1R-mediated effects were observed in the middle to
late stage of cochlear development and were dependent on the
PI3K/Akt pathway but not on the MEK/ERK pathway, as indi-
cated by detection of phosphorylated downstream of IGF1R and
by inhibitor experiments (Okano et al., 2011). In contrast, the
growth and proliferative effects of IGF-1 on otocysts and its
survival effects in proliferative otic neuroblasts during the early
developmental stage were dependent on the MEK/ERK pathway
(Leon et al., 1998; Sanz et al., 1999; Magarinos et al., 2010) and the
PI3K/AKT pathway (Aburto et al., 2012), respectively. The effec-
tor molecules of IGF-1 in the late stage of cochlear development
have been studied using comprehensive gene expression analysis;
several transcriptional factors (FoxM1, Mef2a, and Mef2d) have
been identiﬁed as effectors of IGF-1 signaling (Sanchez-Calderon
et al., 2010).
The physiological functions of IGF-1 and its downstream sig-
naling included the induction of proliferation in the development
of the inner ear. Since postnatal inner earHCsor SCs lose their pro-
liferation potency, particularly in the cochlea (Ruben, 1967), and
as that prevents the regeneration of mammalian HCs after birth,
IGF-1 may contribute to postnatal HC regeneration in mammals.
Additionally, survival effects (anti-apoptotic effects) may con-
tribute to the prevention of HC death after exposure to several
types of conditions that cause inner ear pathology, including noise,
ischemia, and toxic drug treatment, because these conditions usu-
ally cause apoptosis in HCs. Addition of IGF-1 to explant cultures
of mature avian vestibular epithelia caused three-fold upregula-
tion of DNA synthesis after a 48-h treatment but the numbers
of [3H]-thymidine-incorporating cells were similar between 5-h-
and 2-day-treatments, suggesting that IGF-1 did not contribute
to the survival of the sensory epithelium (Oesterle et al., 1997).
Explant cultures of avian auditory epithelia did not show this
increase in DNA synthesis (Oesterle et al., 1997). Induction of
proliferation was observed in neonatal rat dissociated vestibular
SCs that had been treated with IGF-1 although other growth fac-
tors, including epidermal growth factor and transforming growth
factor α, did not show any proliferative effects (Zheng et al., 1997).
This experiment suggested that IGF-1 was a candidate molecule
for inducing regeneration of even postnatal mammalian inner
ear HCs.
Explant culture of adult mammalian cochlea causes loss of
outer HCs due to apoptosis even after a short culture period.
Treatment with IGF-1 as well as acidic ﬁbroblast growth factor,
epidermal growth factor, and transforming growth factors β1 pre-
vented the loss of outerHCs, suggesting the survival effect of IGF-1
on mature mammalian outer HCs (Malgrange et al., 2002). The
survival effect of IGF-1 against aminoglycoside-induced severeHC
losswas observed in explant cultures of postnatalmammalianutri-
cle (Park et al., 2007; Angunsri et al., 2011) and in vivo vestibular
systems of mature guinea pigs (Kopke et al., 2001). In the case of
the in vivo experiments, the perilymph of the mature guinea pig
inner ear was infused with mixture of transforming growth factor
α, IGF-1, and retinoic acid after injury induced by aminoglycoside,
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and functional as well as morphological recovery of HCs was
observed (Kopke et al., 2001).
IN VIVO APPLICATION OF IGF-1 FOR COCHLEAR DAMAGE
The successful application of IGF-1 to the treatment of
aminoglycoside-induced mammalian vestibular HC damage sug-
gested that IGF-1 was an effective molecule for use in inner ear
disorders. However, unilateral peripheral vestibular damage can
be compensated by the central nervous system and the demand
for treatment of an affected vestibular system is less than in the
case of the auditory system, where compensation never occurs.
Moreover, unlike in the cochlea, mature mammalian vestibu-
lar sensory epithelia have the capacity to regenerate (Forge et al.,
1993; Warchol et al., 1993) although this capacity is not markedly
strong. Treatment of cochlear damage is more challenging. In a
study of vestibular systems, IGF-1 was delivered as single recom-
binant molecule, because IGF-1 is a relatively stable molecule
compared with insulin. However, the half-life of IGF-1 is about
8–16 h (Laron, 1999). For inner ear treatment, local application
of IGF-1 is a more preferable drug delivery method compared
with systemic delivery, because blood ﬂow of inner ears is only
1/10000 to 1/1000000th of the systemic ﬂow. Considering these
conditions, gelatin hydrogel (Young et al., 2005) has been used
to achieve efﬁcient local application of IGF-1 into the animal
or human cochlea (Iwai et al., 2006; Lee et al., 2007; Fujiwara
et al., 2008; Nakagawa et al., 2010). In a gelatin hydrogel drug
delivery system, sufﬁcient IGF-1 levels are detected in the per-
ilymph until at least 3 days after application of IGF-1 within
the hydrogel to the round window of the cochleae (Lee et al.,
2007).
First of all, IGF-1 was applied 3 days prior to noise exposure in
mature rat (Iwai et al., 2006). Threshold shifts for 16 and 32 kHz
were signiﬁcantly smaller in the IGF-1 group at 7 days after noise
exposure. Histological evaluation showed that outer HC loss was
signiﬁcantly milder in all turns of the cochleae in the IGF-1 group
than in the control group. These results indicated that local appli-
cation of IGF-1 had positive effects on the protection of outer
HCs against noise exposure and, in turn, caused reduced thresh-
old shifts in the hearing ability of adult rats. Next, IGF-1 was
applied into the adult guinea pig cochlea 5 h after noise exposure
(Lee et al., 2007). It is important to conﬁrm whether the treat-
ment had effects even after noise exposure because prophylactic
application of a drug is sometimes difﬁcult in clinical practice.
Similar to the previous study, threshold shifts due to noise expo-
sure were signiﬁcantly attenuated and outer HC cell loss was also
signiﬁcantly reduced by the IGF-1 treatment. These two experi-
ments clearly showed that IGF-1 applicationusing gelatin hydrogel
was a promising candidate treatment for noise-induced hearing
loss.
Insulin-like growth factor-1 application has also been studied
in a cochlear ischemia and reperfusion injury model in Mongolian
gerbils (Fujiwara et al., 2008), which represents hearing loss simi-
lar to sudden deafness in humans (Hakuba et al., 1997; Koga et al.,
2003). In this study, threshold shifts, assessed by auditory brain
stemresponse,were signiﬁcantly attenuated in an IGF-1-treatment
group, similar to that observed in the noise exposure model. How-
ever, there were some points of difference between the effects of
IGF-1 on noise exposure and ischemic injuries of the cochlea.
First, threshold attenuation occurred 1 day after the injury in the
ischemic and reperfusion model. In contrast, it occurred only
14 days after noise exposure. Second, rescued HC types were dif-
ferent between these two conditions: inner and outer HC loss was
attenuated in ischemic and noise exposure models, respectively.
These results suggested several points about the effect of IGF-1
on SNHL. (1) IGF-1 has the ability to affect both the early and
late phase of SNHL. (2) IGF-1 treatment has potency to protect
both inner and outer HCs from damage. (3) IGF-1 has effects on
different mammals, viz., rats, guinea pigs, and Mongolian gerbils.
MECHANISMS BY WHICH HC NUMBERS ARE MAINTAINED
BY IGF-1 TREATMENT
Cochlear explant culture systems are suitable for analyzing the
mechanisms underlying treatment effects because timing of drug
application or sample collection is easier to control than in
vivo experimental models. Therefore, the mechanisms underly-
ing the positive effects of IGF-1 on cochlear HCs were evaluated
using cochlear explant cultures (Hayashi et al., 2013). In this sys-
tem, cochlear explant cultures were established from neonatal
mice and aminoglycoside was used to induce damage to HCs.
IGF-1 treatment resulted in the maintenance of both inner and
outer HC numbers after aminoglycoside treatment, which was
similar to its effects on noise exposure and ischemic injury in
in vivo experiments. Speciﬁc inhibitors of PI3K, Akt, or ERK
were used with IGF-1 to elucidate which downstream signaling
pathways of IGF1R were involved in the protective effects of IGF-
1 (Figure 1). Different agents were used to inhibit either the
PI3K/Akt or MEK/ERK pathways. The PI3K inhibitor, LY294002,
and the Akt inhibitor, Akt inhibitor VIII, were used to inhibit
the PI3K/Akt pathway. For the MEK/ERK pathway, two differ-
ent ERK inhibitors (U0126 and PD98059) were used. Either
treatment caused attenuation of HC-protection effects, indicat-
ing that both pathways were involved in the maintenance of HC
numbers. These results are different from the roles of IGF-1 in
the development the cochlea, where only the PI3K/Akt pathway
was involved at a later stage (Okano et al., 2011), and sug-
gested that treatment with IGF-1 is a more efﬁcient method
for protecting HCs than the activation of a single signal cas-
cade although the activation of a single pathway is effective for
HC protection (Battaglia et al., 2003; Jiang et al., 2006; Seliv-
anova et al., 2007). Among several inhibitors used, Akt inhibitor
treatment attenuated only the inner HC protection effect, sug-
gesting that Akt is involved in only the maintenance of inner
HCs. A study of the localization of phosphorylated Akt and
phosphorylated ERK using antibodies to these molecules deter-
mined that both Akt and ERK were activated not in HCs,
but in SCs. Akt was activated in the inner sulcus cells that
are located adjacent to inner HCs. In contrast, ERK was acti-
vated in Hensen’s and Claudius’ cells that are located lateral
to the outer HCs. The localization of phosphorylated Akt-
positive cells was consistent with the experiment in which an
Akt inhibitor was used and indicated that Akt is an impor-
tant signal for the protection of inner HCs. These results also
raised the question about how IGF-1 protected HCs. One of the
hypotheses is that IGF-1 acts on SCs and SCs, in turn, secrete
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some factors or express signal-transducing proteins on the mem-
brane and these factors or proteins induce HC maintenance or
regeneration.
There are two possible mechanisms involved in the mainte-
nance of HC numbers. One is the inhibition of cell death and
the other is the proliferation of HCs themselves or transdiffer-
entiation of SCs into HCs after SC proliferation. Involvement
of these two mechanisms has also been studied using cochlear
explant cultures (Hayashi et al., 2013). These results showed
that apoptosis of HCs was signiﬁcantly inhibited in the IGF-1-
treated group and, surprisingly, induction of cell-cycle promo-
tion was also observed in the epithelium of postnatal cochlear
explants. The latter result was inconsistent with the physiolog-
ical characteristics of postnatal mammalian cochleae, but cell
cycle promotion was conﬁrmed by two different methods, i.e.,
5-bromo-2′-deoxyuridine (BrdU) incorporation and phosphohi-
stone H3 immunostaining. In addition, treatment with two differ-
ent proliferation inhibitors, aphidicolin or L-mimosine, caused
attenuation of only outer HC number maintenance. Together
with the ﬁnding that all BrdU-positive cells were observed in
Hensen’s and Claudius’ cells adjacent to outer HCs, this indi-
cated that promotion of the cell cycle in the cochlea by IGF-1
contributed to maintenance of the outer HCs only and that
transdifferentiation of SCs into HCs after SC proliferation may
be the mechanism involved. The MEK/ERK pathway is likely
to be involved in the cell cycle promotion in Hensen’s and
Claudius’ cells, as deduced from two ﬁndings: phosphorylated
ERK, which indicates the activation of the MEK/ERK pathway,
was detected in Hensen’s and Claudius’ cells where BrdU incorpo-
ration and phophohistone H3 were detected, and the proliferation
of SCs was caused by activation of the MEK/ERK pathway in
chicken basilar papillae, resulting in the regeneration of HCs
(Bell and Oberholtzer, 2010).
The target molecules of by which IGF-1 maintains the num-
bers of HCs were identiﬁed using comprehensive analysis of gene
expression in explant cultures treated with IGF-1 (Hayashi et al.,
2014). The expression of two molecules, Netrin1 and Gap43,
was signiﬁcantly up-regulated in the IGF-1-treated group and
the result was conﬁrmed by quantitative reverse transcriptase-
polymerase chain reaction. Upregulation of gene expression was
reduced by inhibition of both the MEK/ERK and PI3K/AKT path-
ways, indicating that the target molecules of IGF-1 were regulated
by both pathways. Netrin1 is a secreted molecule that exerts its
effects through its speciﬁc receptors. Originally, it was described
as being involved in axon guidance of the nervous system (Hedge-
cock et al., 1990), but recent reports have shown its beneﬁcial
effects in injured organs, including the kidney. In the kidney,
translation of Netrin1 is induced in response to reperfusion injury
through the activation of theMEK/ERKpathway (Jayakumar et al.,
2011), and Netrin1 increases the proliferation and migration of
renal proximal tubular epithelial cells (Wang et al., 2009b). More-
over, overexpression of Netrin1 protects the kidney from ischemia
and reperfusion injury (Wang et al., 2009a). Since the effect of
HC protection by IGF-1 was achieved through cell cycle promo-
tion and inhibition of apoptosis (Hayashi et al., 2013), Netrin1
is the probable effector molecule of IGF-1 during cochlear HC
protection.
CLINICAL TRIAL OF IGF-1 FOR SSHL
Based on these in vivo and in vitro studies, a clinical trial was per-
formed to study the efﬁcacy of IGF-1 in the treatment of SNHL
(University Hospital Medical Information Network Clinical Tri-
als Registry under trial registration number UMIN000000936;
Nakagawa et al., 2010, 2012). In this clinical trial, 25 patients
with SSHL that was refractory to systemic steroid therapy were
recruited and IGF-1 was applied onto the round window mem-
brane, using gelatin hydrogel, as performed in in vivo animal
studies (Iwai et al., 2006; Lee et al., 2007; Fujiwara et al., 2008).
The outcome of IGF-1 treatment was compared with that of a
historical control after hyperbaric oxygen therapy where 66 out of
199 patients (33%) showed the hearing threshold improvement
(Nakagawa et al., 2010). In this trial, improvement of hearing
threshold was deﬁned as recovery of more than 10 dB in the
mean hearing level at the ﬁve frequencies tested (0.25, 0.5, 1.0,
2.0, and 4.0 kHz). At 12 and 24 weeks after IGF-1 treatment,
the proportions of patients showing hearing improvement was 48
and 56%, respectively. No serious adverse effects were observed.
The proportion of hearing improvement at 24 weeks after IGF-1
treatment was signiﬁcantly better than that of the historical con-
trol. Analyses of recovery of threshold in each frequency tested
revealed that the thresholds for lower frequencies recovered better
than those for higher frequencies (Nakagawa et al., 2012). Average
recovery in pure tone audiometry thresholds over the ﬁve fre-
quencies tested was 11.9 dB (Nakagawa et al., 2012), which was
comparable to the average threshold recovery previously reported
for intra-tympanic steroid injection (5–22dB).A randomized clin-
ical trial, comparing the efﬁcacy of topical IGF-1 treatment with
that of intra-tympanic steroids for SSHL that is refractory to sys-
temic steroids, is now underway, involving about 120 patients
from all over Japan (University Hospital Medical Information
Network Clinical Trials Registry under trial registration number
UMIN000004366).
CONCLUSION
In conclusion, IGF-1 is a promising medication for SNHL. IGF-1
activates both its downstream signaling pathways, the MEK/ERK
and PI3K/Akt pathways in the cochlea, which causes more efﬁcient
effects on HC protection than activation of a single signal cascade.
IGF-1 protects HCs from various injuries to the inner ear, includ-
ing noise exposure, ischemia, and aminoglycoside treatment. A
clinical trial of IGF-1 treatment on human SSHL as well as in vivo
animal experiments has conﬁrmed its efﬁcacy against HC injuries.
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